Tumor necrosis factor-α-mediated severity of idiopathic retinal periphlebitis in young adults (Eales-disease): implication for anti-TNF-α therapy

详细信息    查看全文

• 作者：Sandeep Saxena (1)
  Aditya B. Pant (2)
  Vinay K. Khanna (2)
  Kamlesh Singh (3)
  Rajendra K. Shukla (2)
  Carsten H. Meyer (4)
  Vijay K. Singh (5)
  
• 关键词：Cytokine ; Idiopathic retinal periphlebitis ; Eales-disease ; Tumor necrosis factor ; α ; Anti ; TNF ; α therapy
• 刊名：Journal of Ocular Biology, Diseases, and Informatics
• 出版年：2010
• 出版时间：March 2010
• 年：2010
• 卷：3
• 期：1
• 页码：35-38
• 全文大小：141KB
• 参考文献：1. Gieser SC, Murphy RP. Eales' disease. In: Ryan SJ, editor. Retina Vol II. Medical retina. St. Louis: CV Mosby; 1994.
  2. Atmaca LS, Idil A, Gunduz K. Visualization of retinal vasculitis in Eales disease. Ocul Immunol Inflamm. 1993;1:41-. CrossRef
  3. Bali T, Saxena S, Kumar D, Nath R. Response time and efficacy of oral methotrexate pulsed therapy in idiopathic retinal periphlebitis. Eur J Ophthalmol. 2005;15:374-.
  4. Saxena S, Rajasingh J, Biswas S, Kumar D, Shinohara T, Singh VK. Cellular response to retinal S-antigen and interphotoreceptor retinoid binding protein fragments in patients with Eales' disease. Pathobiology. 1999;67:37-4. CrossRef
  5. Saxena S, Srivastava P, Kumar D, Khanna VK, Seth PK. Decreased platelet membrane fluidity in retinal periphlebitis in Eales-disease. Ocul Immunol Inflamm. 2006;14:113-6. CrossRef
  6. Saxena S, Kumar D. A new staging system for idiopathic retinal periphlebitis. Eur J Ophthalmol. 2004;14:236-.
  7. Inomata H, Ishibashi T, Murata T, Iwasaki M, Tahara A, Hata K, et al. Intraocular neovascularization. Nippon Ganka Gakkai Zasshi. 1997;101:906-6.
  8. Kawashima M, Shoji J, Kamura Y, Sato Y. Role of chemokines in the vitreous of proliferative diabetic retinopathy. Nippon Ganka Gakkai Zasshi. 2005;109:596-02.
  9. Rai G, Saxena S, Kumar H, Singh VK. Human retinal S-antigen: T cell epitope mapping in posterior uveitis patients. Exp Mol Pathol. 2001;70:140-. CrossRef
  10. Tripathi P, Saxena S, Yadav VS, Naik S, Singh VK. Human S-antigen: peptide determinant recognition in uveitis patients. Exp Mol Pathol. 2004;76:122-. CrossRef
  11. Armstrong D, Ueda T, Ueda T, et al. Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-alpha, vascular endothelial growth factor and platelet-derived growth factor. Angiogenesis. 1998;2:93-04. CrossRef
  12. Dinarello CA. Proinflammatory cytokines. Chest. 2000;118:503-. CrossRef
  13. Saxena S, Pant AB, Khanna VK, Singh K, Kumar D, Singh VK. Interleukin-1 and tumor necrosis factor-alpha: novel targets for immunotherapy in Eales-disease. Ocul Immunol Inflamm. 2009;17:201-. CrossRef
  14. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell. 1988;53:45-3. CrossRef
  15. Tang P, Hung MC, Klostergaard J. Human pro-tumor necrosis factor is a homotrimer. Biochemistry. 1996;35:8216-5. CrossRef
  16. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385:729-3. CrossRef
  17. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487-01. CrossRef
  18. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10:45-5. CrossRef
  19. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science. 2002;296:1634-. CrossRef
  20. Gaur U, Aggarwal BB. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol. 2003;66:1403-. CrossRef
  21. Hunter CA, Timans J, Pisacane P, Menon S, Cai G, Walker W, et al. Comparison of the effects of interleukin-1 alpha interleukin-1 beta and interferon-gamma inducing factor on the production of interferon-gamma by natural killer. Eur J Immunol. 1997;27:2787-2. CrossRef
  22. Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina. 2007;27:399-13. CrossRef
  23. Le Thi HD, Cassoux N, Lebrun-Vignes B, Wechsler B, Bodaghi B, Lehoang P, et al. Therapy of chronic non infectious uveitis. Rev Med Intern. 2007;28:232-1. CrossRef
  
• 作者单位：Sandeep Saxena (1)
  Aditya B. Pant (2)
  Vinay K. Khanna (2)
  Kamlesh Singh (3)
  Rajendra K. Shukla (2)
  Carsten H. Meyer (4)
  Vijay K. Singh (5)
  
  1. Department of Ophthalmology, CSM Medical University, Lucknow, 226 003, India
  2. Indian Institute of Toxicological Research, Lucknow, India
  3. KGMC Institute of Clinical Epidemiology, CSM Medical University, Lucknow, India
  4. Department of Ophthalmology, University of Bonn, Bonn, Germany
  5. Radiation Countermeasures Program, Armed Forces Radiobiology Research Institute, Bethesda, MD, USA
  

文摘

Tumor necrosis factor-alpha (TNF-α) is a pleiotropic inflammatory cytokine. Tumor necrosis factor-alpha was evaluated in the serum samples of patients with idiopathic retinal periphlebitis in young adults (Eales-disease). Retinal periphlebitis was graded according to a new grading system based on severity of inflammation (grade 1-). Quantification of the TNF-α levels was carried out using ELISA kit in the serum samples of young adults with idiopathic retinal periphlebitis (n--7) and healthy controls (n--7) of similar age. Tumor necrosis factor-α level was found to be significantly raised in cases with retinal periphlebitis as compared with controls (p-lt;-.001). Higher levels of TNF-α were found to be associated with increased severity of retinal periphlebitis. Tumor necrosis factor-α represents a novel target for controlling inflammatory activity in idiopathic retinal periphlebitis. Higher levels of TNF-α, in association with the increased severity of retinal periphlebitis, have implications for early anti-TNF-α therapy.